Sign In
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- US Share Prices
- Stock Tips
- Share Chat
- FX
- News & RNS
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
IN BRIEF: Arix Bioscience Notes Positive Data From Amplyx's Study
Arix Bioscience PLC - healthcare investor - Says portfolio company Amplyx Pharmaceuticals announced positive topline data from a phase 2 clinical trial of fosmanogepix as a first-line treatment for patients with invasive fungal infections caused by Candida. The trial met its primary efficacy endpoint, demonstrating a treatment success rate of 80%. Fosmanogepix was well tolerated with no treatment-related serious adverse events or discontinuations.
Current stock price: 86.50 pence
Year-to-date change: down 19%
By Lucy Heming;Â lucyheming@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
Shares in this article
Latest News
- Ocado Group lines up successor to CEO Steiner, Sky News reports
1 hour ago - WRAPUP 10-Trump threatens Iran with fresh strikes as Vance leads peace talks in Switzerland
1 hour ago - Starmer set to resign as early as Monday - reports
9 hours ago - After the fracture: how Britain's financial industry recovered from Brexit
9 hours ago - UK PM Starmer in sustained pressure amid reports could quit next week
11 hours ago - Report says UK PM Starmer ready to quit, but source says he is still focused on the job
18 hours ago - Nine people remain in critical condition after fatal UK train crash
1 day ago
Related News
IN BRIEF: Arix Bioscience shares suspended ahead of RTW takeover
Arix Bioscience PLC - London-based venture capital firm focused on biotechnology companies - Shares suspended from the London Stock Exchange amid the ...
Rtw Biotech
Mears
IN BRIEF: RTW Biotech completes Arix investment in takeover run-up
RTW Biotech Opportunities Ltd - New York-based investment firm focused on the life sciences sector - Says it completed on Friday its previously announ...
Follow the stocks
